Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222533 | 0.92 | KMT2A (0.31) | KMT2ARARBRARG | |
| SCHEMBL6246415 | 0.86 | RARB (0.32) | RARBRARGTSHRNPSR1 | |
| SCHEMBL6281691 | 0.84 | TSHR (0.33) | RARBRARGTSHRNPSR1 | |
| SCHEMBL15330888 | 0.81 | RARB (0.33) | KMT2ARARBRARGTSHRNPSR1 | |
| SCHEMBL6219539 | 0.78 | RARB (0.31) | RARBRARG | |
| SCHEMBL6221267 | 0.77 | TSHR (0.31) | RARBRARGTSHRNPSR1 | |
| SCHEMBL6457990 | 0.77 | TSHR (0.31) | RARBRARGTSHRNPSR1 | |
| SCHEMBL6220876 | 0.76 | RARB (0.37) | RARBRARG | |
| SCHEMBL6248065 | 0.75 | HDAC3 (0.44) | RARBRARG | |
| SCHEMBL5766132 | 0.75 | RARB (0.31) | RARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546143-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004026864-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | KMT2A 480/4885RARB 653/4885RARG 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.